Show simple item record

FieldValueLanguage
dc.contributor.authorWolf, J
dc.contributor.authorNicholls, J
dc.contributor.authorHunter, P
dc.contributor.authorNguyen, DT
dc.contributor.authorKeall, P
dc.contributor.authorMartin, J
dc.date.accessioned2020-07-11
dc.date.available2020-07-11
dc.date.issued2019-01-01en_AU
dc.identifier.urihttps://hdl.handle.net/2123/22847
dc.description.abstractBackground and purpose: Accurate delivery of radiotherapy is critical to achieve optimal treatment outcomes. Interfraction translational IGRT is now standard, and intrafraction motion management is becoming accessible. Some platforms can report both translational and rotational movements in real time. This study aims to quantify the dosimetric impact of observed intrafraction rotation of the prostate measured using monitoring software. Materials and methods: A dose grid resampling algorithm was used to model the dosimetric impact of prostate rotations for 20 patients on a SBRT prostate clinical trial. Translations were corrected before and during treatment, but rotations were not. Real time rotation data were acquired using KIM and a cumulative histogram analysis performed. Prostate volumes were rotated by the range of observed angles and used to calculate DVH data. Results: The pitch axis had a higher range of observed rotations resulting in only 7 patients spending at least 90% of the beam on time across all fractions within rotation angles resulting in PTV D95% ≥36 Gy in this axis. The yaw and roll axes saw 17 and 15 patients respectively achieving this criterion. All but one of 20 patients exceeded CTV D98% ≥36 Gy for all observed rotation angles. Conclusions: Current CTV-PTV margins do not result in compromised CTV dose coverage due to inter and intrafraction prostate rotations in the absence of other uncertainties. Reduced PTV dosing is due to the extremely conformal treatment delivery but is unlikely to be clinically deleterious. Prostate standard IGRT should continue to focus on correcting any observed translational movements. Margin reduction could be explored in conjunction with other uncertainties.en_AU
dc.language.isoenen_AU
dc.publisherElsevieren_AU
dc.relation.ispartofRadiotherapy & Oncologyen_AU
dc.rightsCopyright All Rights Reserveden_AU
dc.subjectDosimetryen_AU
dc.subjectSBRTen_AU
dc.subjectProstateen_AU
dc.titleDosimetric impact of intrafraction rotations in stereotactic prostate radiotherapy: A subset analysis of the TROG 15.01 SPARK trial.en_AU
dc.typeArticleen_AU
dc.subject.asrc0299 Other Physical Sciencesen_AU
dc.identifier.doi10.1016/j.radonc.2019.04.013
dc.relation.nhmrc1112096
dc.relation.other108
usyd.facultySeS faculties schools::Faculty of Medicine and Health::Central Clinical Schoolen_AU
usyd.departmentACRF Image X Instituteen_AU
usyd.citation.volume136en_AU
usyd.citation.spage143en_AU
usyd.citation.epage147en_AU
workflow.metadata.onlyNoen_AU


Show simple item record

Associated file/s

Associated collections

Show simple item record

There are no previous versions of the item available.